The patient's anastrozole compliance to therapy (PACT) program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1505-1512

  Hadji, P ^a   Blettner, M ^b   Harbeck, N ^c   Jackisch, C ^d   Luck H J ^e   Windemuth Kieselbach, C ^f   Zaun, S ^g   Kreienberg, R ^h  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Klinikum Offenbach   (Germany)

^e Gyn Oncological Practice Hanover   (Germany)

^f ALCEDIS GMBH   (Germany)

^g ASTRAZENECA   (United Kingdom)

^h UNIVERSITY OF ULM   (Germany)

Author keywords

Adherence; Anastrozole; Breast cancer; Compliance; Endocrine therapy; Persistence

Indexed keywords

ANASTROZOLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT CODING; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; TREATMENT OUTCOME; VASCULAR DISEASE;

ADHERENCE; ANASTROZOLE; BREAST CANCER; COMPLIANCE; ENDOCRINE THERAPY; PERSISTENCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; PATIENT COMPLIANCE; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 84878427869     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds653     Document Type: Article

References (28)

1. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 2008; 15: 73-90.
2. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization 2003; http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf (5 November 2012, date last accessed)
3. Balkrishnan R. The importance of medication adherence in improving chronicdisease related outcomes: what we know and what we need to further know. Med Care 2005; 43: 517-520.
4. Haynes RB, Ackloo E, Sahota N et al Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; CD000011. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000011.pub3/pdf
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
6. Carlson RW, Allred DC, Anderson BO et al National Comprehensive Cancer Network Clinical Practice Guidelines in oncology: breast cancer (version 3.2012), 2012; http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (5 November 2012, date last accessed)
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
8. Partridge AH, Avorn J, Wang PS et al Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661.
9. Buzdar AU, Coombes RC, Goss PE et al. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008; 112: 700-709.
10. Chlebowski R, Cuzick J, Amakye D et al Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009; 18 (Suppl 2): S1-S11.
11. Burstein HJ, Prestrud AA, Seidenfeld J et al American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796.
12. Buzdar A, Cuzick J, Sestak I et al Ten-year analysis of the ATAC trial. ASCO Breast Cancer Symposium (Abstr 256). National Harbor, MD, 2010.
13. Cuzick J, Sestak I, Baum M et al Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141.
14. Forbes JF, Cuzick J, Buzdar A et al Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
15. Howell A, Cuzick J, Baum M et al Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
16. Hadji P. Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Crit Rev Oncol Hematol 2011; 80: 301-313.
17. Ward JH. Duration of adjuvant endocrine therapy of breast cancer: how much is enough? Curr Opin Obstet Gynecol 2010; 22: 51-55.
18. Hershman DL, Kushi LH, Shao T et al Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-4128.
19. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66.
20. Ziller V, Kalder M, Albert US et al Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20: 431-436.
21. Hadji P, Ziller V, Kalder M et al Non-compliance in der adjuvanten endokrinen Therapie des Mammakarzinoms. Teil 1. Frauenarzt 2007; 48: 146-150.
22. Harbeck N, Blettner M, Hadji P et al Patient's Anastrozole Compliance to Therapy Program (PACT): methods and baseline results from a population-based, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormone-sensitive early breast cancer. Breast Care (accepted for publication).
23. Partridge AH, LaFountain A, Mayer E et al Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-562.
24. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2010; 125: 191-200.
25. Partridge AH, Wang PS, Winer EP et al Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21: 602-606.
26. Gold DT, McClung B. Approaches to patient education: emphasizing the longterm value of compliance and persistence. Am J Med 2006; 119: S32-S37.
27. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010; 73: 156-166.
28. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002; 29 (Suppl 1): S2-S10.